KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accounts Payables: 2018-2024

Historic Accounts Payables for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $51.6 million.

  • Esperion Therapeutics' Accounts Payables rose 122.33% to $77.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 122.33%. This contributed to the annual value of $51.6 million for FY2024, which is 62.84% up from last year.
  • As of FY2024, Esperion Therapeutics' Accounts Payables stood at $51.6 million, which was up 62.84% from $31.7 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Accounts Payables peaked at $52.0 million during FY2020, and registered a low of $17.6 million during FY2021.
  • Its 3-year average for Accounts Payables is $35.5 million, with a median of $31.7 million in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 80.12% in 2020, then tumbled by 66.22% in 2021.
  • Esperion Therapeutics' Accounts Payables (MRY) stood at $52.0 million in 2020, then crashed by 66.22% to $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then soared by 37.66% to $31.7 million in 2023, then skyrocketed by 62.84% to $51.6 million in 2024.
  • Its last three reported values are $51.6 million in FY2024, $31.7 million for FY2023, and $23.0 million during FY2022.